Angela Espitia

Angela Espitia

Auto-generated profile, based on publicly available information

Angela Espitia

Department of Respiratory Medicine, International Hospital of Colombia, Fundación Cardiovascular de Colombia, Piedecuesta, Santander, Colombia

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018 in La Revue de Médecine Interne
Verified
Journal Article
Closed access
PPP. Pottier
P. Pottier
FAF. Cohen Aubart
F. Cohen Aubart
OSO. Steichen
O. Steichen
MDM. Desprets
M. Desprets
MPM. Pha
M. Pha
JHJ.B. Hardouin
J.B. Hardouin

1 January 2021 in Medical Devices: Evidence and Research
Verified
Journal Article
Open access
PDF file
ARAlba Ramírez-Sarmiento
Alba Ramírez-Sarmiento
OAOrlando Aya
Orlando Aya
DCDiana Cáceres-Rivera
Diana Cáceres-Rivera
CRCarlos F Reyes
Carlos F Reyes
AEAngela Espitia
Angela Espitia
MOMauricio Orozco-Levi
Mauricio Orozco-Levi
Background: Bronchoaspiration of content that accumulates in the supraglottic area (eg, saliva, gastroesophageal reflux) is a risk factor for ventilator-associated pneumonia. A continuous supraglottic suction system may decrease the risk of bronchoaspiration in these patients. Objective: (1) Constructing a conceptual model and functional prototype of a continuous supraglottic suction device for use in humans; (2) defining functional characteristics in ex vivo swine head models; and (3) evaluating its efficacy and safety in mechanically ventilated patients. Methods: Study conducted in three phases. First phase: definition of distances and diameters of the triangle determined by dental arch, posterior oropharynx and vallecula, and diameter of the oropharynx in axial projection; and identification of the declining area of supraglottic suction. Second phase: design engineering and functional prototype evaluated in ex vivo models. Third phase: evaluation of device use in terms of safety and efficacy in ventilated patients. Results: We obtained a final functional model of the SUPRAtube device injected into PVC for medical use. Device effectiveness in in vitro simulation showed a high and fast suction capacity of liquid and thick volumes. Study of swine heads allowed to validate the shape, size and functional fenestration of the device. Study in intubated and mechanically ventilated patients showed a high supraglottic suction capacity and the absence of local adverse events during 72 (7-240) hours of continuous operation. Conclusion: Our study describes the process of conceptualization, design and production of a practical, safe, low-cost continuous supraglottic suction device without representing anti-biotic pressure, which appears to be a new complementary preventive strategy for the standard management of intubated and mechanically ventilated patients.

1 March 2025 in Medical Devices: Evidence and Research
Verified
Journal Article
Open access
PDF file
MOMauricio Orozco-Levi
Mauricio Orozco-Levi
DTDiana Carolina Tiga-Loza
Diana Carolina Tiga-Loza
OAOrlando Aya
Orlando Aya
CRCarlos Fernando Reyes
Carlos Fernando Reyes
DCDiana Cáceres-Rivera
Diana Cáceres-Rivera
ARAlba Ramírez-Sarmiento
Alba Ramírez-Sarmiento
Objective: To evaluate the efficacy and safety of the SUPRAtube innovation device in preventing ventilator associated events and fluid accumulation in the supraglottic region in patients receiving mechanical ventilation (MV) through orotracheal tubes. Methods: Multicenter, controlled, randomized, parallel, open-label clinical trial with a 1:1 allocation ratio of MV patients compared the use of the SUPRAtube elastomeric device with standard care and aspiration techniques. A series of computer-random numbers and centralized allocation with sealed envelopes were used. Setting: Adult patients (n=108; mean age: 63 yrs, range: 19– 85) hospitalized in intensive care units of two centers, the Cardiovascular Foundation of Colombia and the International Hospital of Colombia (Santander, Colombia), were included. All patients received MV through orotracheal tubes, were hemodynamically stable, had upper airway integrity according to fiberoptic bronchoscope findings, and had basic coagulation tests within acceptable risk criteria. Interventions: Comprehensive standard of care, including preventive strategies, medical therapy, positive pressure MV, and routine procedures for management of oropharyngeal and pulmonary secretions (humidification, patient mobilization, and airway suctioning), was compared with the standard of care plus continuous supraglottic suction with the new SUPRAtube device. Results: The study period reached five days before extubation (media 85± 7 hours). The weight of the aspirated content was 415 g (P25;P75: 396;536) in the control group and 624 g (P25;P75: 469;824) in the SUPRAtube group (p< 0.001), equivalent to a mean difference of 213 g (P25;P75: 55;569; +50%). The device did not induce adverse events. Conclusion: Continuous supraglottic aspiration using SUPRAtube is complementary, effective, safe, simple, and inexpensive and reduces the accumulation of oropharyngeal secretions in mechanically ventilated patients. The relevant clinical benefit in terms of preventing and improving tracheobronchitis earlier on was demonstrated by sequential fiberoptic bronchoscopy. Registration in Clinical Trials: The present study is registered at clinicaltrials.gov NCT03573609.